Ovarian cancer
GC Jayson, EC Kohn, HC Kitchener, JA Ledermann - The Lancet, 2014 - thelancet.com
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated
death. The disease typically presents in postmenopausal women, with a few months of …
death. The disease typically presents in postmenopausal women, with a few months of …
[HTML][HTML] Imaging biomarker roadmap for cancer studies
JPB O'connor, EO Aboagye, JE Adams… - Nature reviews Clinical …, 2017 - nature.com
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs
used daily in oncology include clinical TNM stage, objective response and left ventricular …
used daily in oncology include clinical TNM stage, objective response and left ventricular …
Antiangiogenic therapy in oncology: current status and future directions
Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been
validated as a target in several tumour types through randomised trials, incorporating …
validated as a target in several tumour types through randomised trials, incorporating …
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Background The international standard of care for women with suspected advanced ovarian
cancer is surgical debulking followed by platinum-based chemotherapy. We aimed to …
cancer is surgical debulking followed by platinum-based chemotherapy. We aimed to …
[HTML][HTML] Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
GJS Rustin, MEL Van Der Burg, CL Griffin, D Guthrie… - The Lancet, 2010 - thelancet.com
Background Serum CA125 concentration often rises several months before clinical or
symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 …
symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 …
Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma
PA Vasey, GC Jayson, A Gordon… - Journal of the …, 2004 - academic.oup.com
Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered
the standard of care for treatment of ovarian carcinoma. We compared the combination of …
the standard of care for treatment of ovarian carcinoma. We compared the combination of …
Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI
Rapid T1‐weighted 3D spoiled gradient‐echo (GRE) data sets were acquired in the
abdomen of 23 cancer patients during a total of 113 separate visits to allow dynamic contrast …
abdomen of 23 cancer patients during a total of 113 separate visits to allow dynamic contrast …
[HTML][HTML] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 …
AM Oza, AD Cook, J Pfisterer, A Embleton… - The Lancet …, 2015 - thelancet.com
Background The ICON7 trial previously reported improved progression-free survival in
women with ovarian cancer with the addition of bevacizumab to standard chemotherapy …
women with ovarian cancer with the addition of bevacizumab to standard chemotherapy …
[HTML][HTML] The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
MO Leach, KM Brindle, JL Evelhoch, JR Griffiths… - British journal of …, 2005 - nature.com
Vascular and angiogenic processes provide an important target for novel cancer
therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used …
therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used …
[HTML][HTML] DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
JPB O'Connor, A Jackson, GJM Parker… - British journal of …, 2007 - nature.com
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently
used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds …
used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds …